European regulator issues positive opinion on lung drug Daxas

04/26/2010 | Wall Street Journal, The

The European Medicines Agency backed Nycomed and Forest Laboratories' application to market lung drug Daxas as maintenance treatment for chronic bronchitis patients with severe chronic obstructive pulmonary disease. European approval would make Daxas the first oral drug in the region for the life-threatening condition.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA